Alastair Kilgour
Co-Founder and Partner @ Parkwalk Advisors
London, United Kingdom
Alastair Kilgour is a Series B investor at Parkwalk Advisors in London focused on Biotechnology and Health Care. Alastair was a Partner of Lazard LLP, Director of BNP and a Founder Partner of Ark Securities. He has analysed and advised hundreds of companies, both private and public, on strategy, development, fund-raising and exits. Alastair has also advised many institutions on their public and private investments, latterly in the smallcap and micro-capspace.Alastair has invested in dozens of private companies over the years, advising management on strategy – both financial and commercial – and helping guide them towards exit, both trade sales and IPO. He was on the advisory team that listed Genentech and Biogen in London, two of the first ‘pure’ University spinouts in the 1980's
- Total investments:
- 44
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries Alastair Kilgour invests in
Stages Alastair Kilgour invests in
Countries Alastair Kilgour invests in
Investment Focus
Industry
- Biotechnology 7 (16%)
- Health Care 6 (14%)
- Medical 4 (9%)
- Life Science 4 (9%)
- Sensor 2 (5%)
Stage
- Series B 8 (18%)
- Series A 7 (16%)
- Seed 4 (9%)
- Series C 4 (9%)
- Funding Round 4 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Brainomix
|
Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time. | $6.5M / Series C / Feb 24, 2026 | |
|
Brainomix
|
Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time. | $18.2M / Series C / Mar 18, 2025 | |
PhoreMost
|
PhoreMost is a new-model drug discovery company based in Cambridge, UK: Using its core expertise to open up new ‘druggable’ target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted’ therapies more efficiently to market and pass these cost savingsonto patients. | $12M / Series B / Sep 12, 2024 | |
Mogrify
|
Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems 2020). The platforms, MOGRIFY® and epiMOGRIFY®, developed over a 12-year period via amulti-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and growth factors required to produce any target human cell type from any source human cell type.The platforms can be used to enhance existing stem-cell forward programming methods, or bypass development pathways altogether, affecting a direct transdifferentiation between a mature cell type to another mature cell type.Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, by delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology, metabolic and other areas of degenerative disease.Uniquely positioned to address a regenerative medicine market estimated to be worth $150 billion USD by 2028, Mogrify is commercializing its technology via a combination of in vivo reprogramming therapy development, co-development partnerships, as well as the exploitation of the platform in other therapeutic and non-therapeutic applications. | $10M / Series A / Oct 02, 2023 | |
Paragraf
|
Paragraf is the world’s leading graphene-based electronic device design, development and manufacturing company. Building on our proprietary process to grow graphene directly on standard semiconductor industry substrates, Paragraf has pioneered the delivery of two-dimensional technologies at scale. Paragraf’s high-quality graphene – integratablewith standard semiconductor tool process lines – has unlocked the incorporation of this remarkable material into both existing and new electronic devices and applications. Through our world-first dedicated graphene device foundry, Paragraf delivers high-performance, low-power technologies to multiple markets and offers two-dimensional-material foundry services to customers and partners, providing graphene in chips to their device requirements. | $60M / Series B / Mar 01, 2022 | |
|
Paragraf
|
Paragraf is the world’s leading graphene-based electronic device design, development and manufacturing company. Building on our proprietary process to grow graphene directly on standard semiconductor industry substrates, Paragraf has pioneered the delivery of two-dimensional technologies at scale. Paragraf’s high-quality graphene – integratablewith standard semiconductor tool process lines – has unlocked the incorporation of this remarkable material into both existing and new electronic devices and applications. Through our world-first dedicated graphene device foundry, Paragraf delivers high-performance, low-power technologies to multiple markets and offers two-dimensional-material foundry services to customers and partners, providing graphene in chips to their device requirements. | Series A / Feb 15, 2022 | |
|
Brainomix
|
Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time. | $21.3M / Series B / Dec 16, 2021 | |
PetMedix
|
PetMedix is a development stage veterinary biopharmaceutical company based in Cambridge, UK. they are using the highest quality science to make the therapies their pets need and deserve, keeping them healthier, happier, and for longer. Building on more than thirty years of world-leading innovation and human drug development, they are applying thecutting edge of science to bring breakthroughs for the animals they love and care for. | $37.2M / Series B / Sep 08, 2021 | |
PredictImmune
|
PredictImmune is developing pioneering tools for guiding treatment options in immune-mediated inflammatory diseases with the first product addressing Inflammatory Bowel Disease (both Crohn’s and ulcerative colitis). Based on world-leading research at Cambridge University, UK, they are developing a simple lab test, using a small blood sample, whichaccurately identifies patients at diagnosis who are at risk of experiencing severe, relapsing disease. These patients are likely to benefit from early biologics therapy. Physicians, patients and payors all recognise the value of such an approach to the management of Inflammatory Bowel Disease. | $7M / Series A / May 12, 2021 | |
|
Mogrify
|
Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems 2020). The platforms, MOGRIFY® and epiMOGRIFY®, developed over a 12-year period via amulti-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and growth factors required to produce any target human cell type from any source human cell type.The platforms can be used to enhance existing stem-cell forward programming methods, or bypass development pathways altogether, affecting a direct transdifferentiation between a mature cell type to another mature cell type.Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, by delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology, metabolic and other areas of degenerative disease.Uniquely positioned to address a regenerative medicine market estimated to be worth $150 billion USD by 2028, Mogrify is commercializing its technology via a combination of in vivo reprogramming therapy development, co-development partnerships, as well as the exploitation of the platform in other therapeutic and non-therapeutic applications. | $17M / Series A / May 04, 2021 | |
| See all 44 investments → | |||
Co-Investors
About Parkwalk Advisors
Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.
Parkwalk Advisors Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Alastair Kilgour
Co-Founder and Partner
|
|||
Alun Williams
Investment Director
|
|||
Chloe Richardson
Investor Relations Manager
|
|||
Douglas Wright
CEO and Co-Founder
|
|||
Enrico D'Angelo
Finance Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Alastair Kilgour invest in?
Alastair Kilgour invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 44 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Alastair Kilgour last invest?
The most recent investment recorded for Alastair Kilgour closed in Feb 2026. Shizune tracks 44 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
